StockWatch
·

Fortress Biotech, Inc. Q1 FY26 Results

FBIOQ1 FY26 Results
Filing
MetricValue ($ M)Q1 FY25
Revenue16.0422.1%
Total Income16.0422.1%
Expenditure23.7832.9%
PBT142.29
Net Profit110.371143.2%
OPM-48.25%
NPM100.00%180.55pp
EPS3.44816.7%
View full financials

Fortress Biotech Reports Q1 2026 Net Income of $108.4 Million

15 May 2026 · 15 May, 1:58 am

Summary

Fortress Biotech announced its financial results for the first quarter ended March 31, 2026, reporting a consolidated net income of $108.4 million, or $3.44 per share (basic) and $2.82 per share (diluted). Consolidated net revenue was $16.0 million, compared to $13.1 million for the same period in 2025. The company highlighted the FDA approval of ZYCUBO® and the sale of Cyprium's PRV for $205 million. Fortress ended the quarter with $255.8 million in cash and cash equivalents.

Key Highlights

  1. 1

    Fortress Biotech reported consolidated net income attributable to common stockholders of $108.4 million for the first quarter of 2026.

  2. 2

    Earnings per share were $3.44 (basic) and $2.82 (diluted) for the first quarter of 2026.

  3. 3

    Consolidated net revenue totaled $16.0 million for the first quarter ended March 31, 2026, compared to $13.1 million for the first quarter of 2025.

  4. 4

    The FDA approved ZYCUBO® for Menkes disease, and Cyprium sold its PRV for $205 million in the first quarter of 2026.

  5. 5

    Fortress' consolidated cash and cash equivalents totaled $255.8 million as of March 31, 2026, an increase of $176.5 million during the quarter.

Management Comments

L

Lindsay A. Rosenwald

M.D.

The first quarter of 2026 marked a pivotal period for Fortress, highlighted by significant execution across our portfolio and meaningful progress in enhancing long‑term shareholder value. The FDA approval of ZYCUBO® for Menkes disease and the subsequent monetization of Cyprium’s PRV for $205 million represent important validation of our business model. We deployed a portion of these proceeds to strengthen our balance sheet through debt reduction, lowering our outstanding principal with Oaktree to $15.0 million. We also continued to expand our pipeline through business development, including Avenue’s acquisition of ATX‑04 from Duke University, a clinically validated program with the potential to address significant unmet need in Pompe disease. Looking ahead, we expect to generate increasing royalty revenue from ZYCUBO® and UNLOXCYT™, along with potential milestone payments across our portfolio. In parallel, AstraZeneca’s regulatory submissions in the EU and Japan for anselamimab (formerly known as CAEL-101), underscore the continued optionality within our partnered assets for potential future sales milestones for Fortress and approval milestones in the U.S. We have a diversified portfolio of commercial, late‑stage, and development‑stage programs and Fortress is well positioned to advance strategic initiatives and drive long‑term value for our shareholders.

Informational and educational content only. Not investment advice.